Significant Hyperglycemia in Hospitalized Total Pancreatectomy Patients: Results of a Pilot Prospective Continuous Glucose Monitoring Study
Authors' conclusion
Hospitalized TP patients spend considerable time above 180 mg/dL demonstrating the unmet need of optimal glucose monitoring in this cohort.
Study context
- Population
- Hospitalized patients after total pancreatectomy (TP) without islet autotransplantation, non-ICU setting, Mayo Clinic, Rochester
- Participants
- 27 patients
- Exposure
- Continuous glucose monitoring (CGM) data <30 days after TP vs ≥30 days after TP
- Outcome
- TIGHT range (140 mg/dL-180 mg/dL)
- Follow-up
- Day 1
Methodological detailspilot, blinded CGM (Dexcom G6 PRO), single-centre
- Pilot
- Blinded CGM (Dexcom G6 PRO)
- Single-centre
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Cohort 1 | Cohort 2 |
|---|---|---|
| TIGHT range (140 mg/dL-180 mg/dL) · days 2-10 | average 23.4% ± 25.8% | average 20.6% ± 25.7% |
TIGHT range (140 mg/dL-180 mg/dL) · days 2-10
- No statistically significant difference
Time above target range · day 1 and days 2-10
- Both cohorts spent the majority of time above target range
- >50%
- No significant differences in CGM metrics between the two cohorts
CGM accuracy vs point-of-care glucose
- Overall mean absolute relative difference
- 19.6% ± 10
- Readings meeting % 20/20
- 68%
- Least accuracy on day 1 of sensor insertion
Safety
- Device-related adverse events
- 0
Original publication
Significant Hyperglycemia in Hospitalized Total Pancreatectomy Patients: Results of a Pilot Prospective Continuous Glucose Monitoring Study. Diabetes Technol Ther. Published 10 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →